Skip to main content

Table 4 Estimation of CLN.HCl in their pharmaceutical preparations using the proposed kinetic methods and reference methods:

From: Validated green spectrophotometric kinetic method for determination of Clindamycin Hydrochloride in capsules

Formula Drug Claim (mg/tab) Recovery % ± S.D* Reference method [3]
Proposed kinetic method
Fixed time Initial rate
Clindo** CLN 75 99.13% ± 2.07
t = 1.76
F = 2.83
98. 97 ± 1.34
t = 1.64
F = 2.87
100.16% ± 0.25
t = 1.42
   150 101.12% ± 0.63
t = 2.08
F = 2.45
100.83% ± 1.36
t = 1.93
F = 2.39
101.16% ± 1.02
t = 1.54
   300 100.18% ± 0.99
t = 1.84
F = 2. 13
100.89% ± 1.03
t = 2.45
F = 1.98
100.75% ± 0.28
t = 1.13
    Fixed time Initial rate  
Clindamycin Biomed*** CLN 75 99.19% ± 0.69
t = 0.16
F = 2.39
100.15% ± 1.38
t = 1.56
F = 2.18
100.53% ± 1.02
t = 0.83
   150 99.25% ± 1.17
t = 1.46
F = 2.37
100.25% ± 0.87
t = 2.10
F = 2.67
101.19% ± 1.00
t = 0.79
   300 100.29% ± 1.19
t = 1.18
F = 2.72
101.50% ± 1.05
t = 1.82
F = 2.28
100.76% ± 0.89
t = 1.09
  1. At 95% confidence limit, t- and F value at five degrees of freedom are t = 2.776 and f = 6.26
  2. *Recovery is the mean of five replicates
  3. **Product Supplied by AL-SAAD pharmaceutical industries, Syria
  4. ***Product Supplied by BIOMED pharmaceutical industries, Syria